Viriom Inc. is a commercial and late development stage biotech company developing novel therapies and prevention treatments against HIV and hepatitis B virus (HBV). Viriom's pipeline includes: Elpida® (elsulfavirine), the best-in-class NNRTI that received its first market authorization in 2017; fixed doze combinations with nucleoside reverse transcriptase inhibitors; an innovative extended release weekly oral formulation; and VM1500A - a long acting injectable therapy and pre-exposure prophylaxis. Viriom is also developing a highly potent prodrug of the antiviral tenofovir (active component of both Vemlidy® and Viread®) to treat HIV and hepatitis B patients. Viriom believes its drug candidates are capable of achieving breakthroughs in treatment and prevention of HIV and chronic HBV infections in both developing and developed countries.
View Top Employees from Viriom IncWebsite | https://www.viriom.com/ |
Revenue | $10 million |
Funding | $7 million |
Employees | 11 (8 on RocketReach) |
Founded | 2009 |
Address | 12760 High Bluff Dr, San Diego, California 92130, US |
Phone | (858) 794-4860 |
Technologies |
JavaScript,
HTML,
Twitter
+9 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Biotechnology, Manufacturing, Science and Engineering, Health Care, Pharmaceutical |
Competitors | Abivax, Alios BioPharma, ONL Therapeutics, Orphazyme A/S, Relmada Therapeutics, Inc |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Viriom Inc employee's phone or email?
The Viriom Inc annual revenue was $10 million in 2024.
C David Pauza is the Chief Science Officer of Viriom Inc.
8 people are employed at Viriom Inc.
Viriom Inc is based in San Diego, California.
The NAICS codes for Viriom Inc are [32, 325, 3254, 32541].
The SIC codes for Viriom Inc are [283, 28].